CNS Pharmaceuticals, Inc.

Equities

CNSP

US18978H2013

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-27 pm EDT 5-day change 1st Jan Change
0.37 USD -1.33% Intraday chart for CNS Pharmaceuticals, Inc. +2.27% -70.87%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
CNS Pharmaceuticals, Inc. Approves the Appointments to its Board Committees CI
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday on Caution Ahead of Fed Meeting, Tech Earnings MT
CNS Pharmaceuticals Prices $4 Million Offering; Shares Fall Pre-Bell MT
CNS Pharmaceuticals, Inc. Appoints Amy Mahery to its Board of Directors CI
CNS Pharmaceuticals, Inc. Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme CI
CNS Pharmaceuticals, Inc. Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin CI
CNS Pharmaceuticals, Inc. Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy CI
CNS Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : CNS Pharmaceuticals, Inc. - Pre Recorded Special Call
CNS Pharmaceuticals, Inc. Opens 46 Clinical Trial Sites Across the U.S., Italy, France, Spain, and Switzerland CI
Cns Pharmaceuticals, Inc. Announces Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme CI
CNS Pharmaceuticals, Inc. Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy CI
CNS Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
CNS Pharmaceuticals, Inc. Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme CI
Top Premarket Gainers MT
CNS Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Bettina M. Cockroft Joins CNS Pharmaceuticals, Inc.'s Board of Directors CI
Transcript : CNS Pharmaceuticals, Inc. - Special Call
Top Premarket Gainers MT
Top Premarket Decliners MT
Top Premarket Gainers MT
CNS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
CNS Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt CI
CNS Pharmaceuticals Says it Has No Exposure to Silicon Valley Bank MT
CNS Pharmaceuticals, Inc. Continues Momentum in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of Gbm with First Patient Enrolled in Switzerland CI
Chart CNS Pharmaceuticals, Inc.
More charts
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system (CNS). The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is in development for the treatment of a number of serious brain and CNS oncology indications, including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. In addition, the Company is advancing the development of its WP1244/WP1874 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents. The Company is also evaluating the use of WP1244/WP1874 in the treatment of other primary brain and central nervous system cancers, as well as cancers metastatic to the brain including pancreatic, ovarian, and lymphomas.
More about the company
  1. Stock
  2. Equities
  3. Stock CNS Pharmaceuticals, Inc. - Nasdaq
  4. News CNS Pharmaceuticals, Inc.
  5. CNS Pharmaceuticals Gets Swiss Approval for Brain Cancer Treatment Study